Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2002-1-21
pubmed:abstractText
Enhanced platelet activity and platelet endothelial interaction are hallmarks of different vascular and metabolic diseases with subsequent thrombus formation. In atherosclerosis, coronary artery disease, congestive heart failure, nitrate tolerance, chronic inflammation, or diabetic states, platelet activation may in part be due to a stimulation of the renin-angiotensin-aldosteron system, which also contributes to enhanced oxidant stress in these conditions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Arachidonic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles, http://linkedlifedata.com/resource/pubmed/chemical/EXP3174, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/Losartan, http://linkedlifedata.com/resource/pubmed/chemical/Phospholipases A, http://linkedlifedata.com/resource/pubmed/chemical/Phospholipases A2, http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Angiotensin, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thromboxane, http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane A2, http://linkedlifedata.com/resource/pubmed/chemical/arachidonyltrifluoromethane, http://linkedlifedata.com/resource/pubmed/chemical/candesartan
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0920-3206
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
301-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:11800413-Angiotensin Receptor Antagonists, pubmed-meshheading:11800413-Animals, pubmed-meshheading:11800413-Arachidonic Acids, pubmed-meshheading:11800413-Benzimidazoles, pubmed-meshheading:11800413-Dogs, pubmed-meshheading:11800413-Dose-Response Relationship, Drug, pubmed-meshheading:11800413-Enzyme Inhibitors, pubmed-meshheading:11800413-Humans, pubmed-meshheading:11800413-Imidazoles, pubmed-meshheading:11800413-Losartan, pubmed-meshheading:11800413-Phospholipases A, pubmed-meshheading:11800413-Phospholipases A2, pubmed-meshheading:11800413-Platelet Activation, pubmed-meshheading:11800413-Platelet Aggregation, pubmed-meshheading:11800413-Platelet Aggregation Inhibitors, pubmed-meshheading:11800413-Receptor, Angiotensin, Type 1, pubmed-meshheading:11800413-Receptors, Angiotensin, pubmed-meshheading:11800413-Receptors, Thromboxane, pubmed-meshheading:11800413-Renin-Angiotensin System, pubmed-meshheading:11800413-Signal Transduction, pubmed-meshheading:11800413-Tetrazoles, pubmed-meshheading:11800413-Thromboxane A2
pubmed:year
2001
pubmed:articleTitle
Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
pubmed:affiliation
Institute of Applied Physiology, Albert-Ludwigs University, Freiburg, Germany. angphys@ruf.uni-freiburg.de
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't